Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Roivant Sciences Ltd (ROIV:NASDAQ), powered by AI.
Roivant Sciences Ltd is currently trading at $30.04. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Roivant Sciences Ltd on Alpha Lenz.
Roivant Sciences Ltd's P/E ratio is -126.7.
“Roivant Sciences Ltd trades at a P/E of -126.7 (undervalued) with modest ROE of -3.2%.”
Ask for details →Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
“Roivant Sciences Ltd trades at a P/E of -126.7 (undervalued) with modest ROE of -3.2%.”
Ask for details →Roivant Sciences Ltd (ticker: ROIV) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 750 employees. Market cap is $21.8B.
The current price is $30.04 with a P/E ratio of -126.71x and P/B of 4.65x.
ROE is -3.23% and operating margin is -3833.27%. Annual revenue is $29M.